Actos (pioglitazone) has been linked with an increased risk of bladder cancer. Actos is a popular diabetes drug sold by Takeda Pharmaceuticals, Inc., and it is also sold in combination with other drugs as Duetact, Actoplus Met, and Actoplus Met XR. Our firm has clients in the $2+ Billion settlement offered by Takeda in 2015. If you or someone you know has suffered due to taking this drug, the lawyers at Rheingold Giuffra Ruffo & Plotkin LLP are here to help you explore your settlement and legal options.
Serving Clients Across the Nation
Actos & Bladder Cancer
Recent studies have found a potential link between Actos and increased risk of bladder cancer. In fact, Actos was pulled from the European market in June, 2011. The FDA is reviewing animal and human data to investigate the connections. At Rheingold Giuffra Ruffo & Plotkin LLP, we have been helping people from New York and across the nation with their most critical legal problems for over 30 years. We are able to handle a wide range of drug liability claims, including those involving the prescription diabetes drug Actos.
Symptoms of bladder cancer can include:
- Abdominal pain
- Blood in the urine
- Bone pain or tenderness
- Painful urination
- Urinary frequency
- Urinary urgency
- Urine leakage (incontinence)
- Weight loss
Our attorneys will work with you personally to determine the extent of the monetary damage this drug has caused you, and what legal remedies are at your disposal. Our goal is to help you obtain monetary compensation for the financial hardships you face.
Our firm has filed suits on behalf of cancer victims in federal courts. These suits are against Takeda Pharmaceuticals America, Takeda Pharmaceuticals North America, Takeda Pharmaceutical Company and Eli Lilly. Lilly and Takeda created a joint sales collaboration in 1999. We allege that an initial animal study revealed drug-induced tumors in male rats. Further, the PROactive study in human users of Actos showed cases of bladder cancer, although the cancer cases were not reported in the published results. In the legal complaints our firm filed, we recount multiple broad medical studies which demonstrated that increased dosing resulted in a higher rate of bladder cancer, with statistical significance being in as short as one to two years. We intend to vigorously pursue investigations as to why Takeda employees made statements that medical studies did not support a connection with bladder cancer, and why high level Takeda management decisions were made to delay any increased warnings with for Actos or recalling the drug outright.